相关实验视频
Updated: Jun 2, 2025

00:07
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
7.2K
准CHEK1:甲状腺癌中的金色化物-Rh2和Cu2O@G-Rh2纳米粒子
Lidong Wang1, Xin Wu1, XinLu Wang2
1Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang, 110004, People's Republic of China.
Cell biology and toxicology
|January 14, 2025
概括
银化物-Rh2纳米颗粒通过向CHEK1,降低细胞活力,并抑制瘤复发,有效抑制甲状腺癌 (THCA). 这种新的方法显示出改善THCA治疗和临床应用的希望.
科学领域:
- 内分泌学 在内分泌学.
- 在瘤学瘤学.
- 纳米技术纳米技术
背景情况:
- 甲状腺癌 (THCA) 发病率正在上升,对于复发性或转移性疾病的选择有限.
- 开发THCA的新型治疗策略至关重要,因为晚期预后不佳.
研究的目的:
- 为了研究金色化物-Rh2 (G-Rh2) 对甲状腺癌的抗癌作用.
- 确定THCA中G-Rh2的分子标,并评估纳米粒子传递系统.
主要方法:
- 网络药理学发现CHEK1是G-Rh2.2的分子标.
- 在体外和体内研究中评估了G-Rh2载入Cu2O纳米粒子 (Cu2O@G-Rh2).
- 评估了细胞活力,细胞亡,DNA损伤和细胞周期控制.
主要成果:
- 金色化物-Rh2显著抑制了THCA细胞的增殖,并诱导了亡.
- Cu2O@G-Rh2纳米颗粒降低了细胞活力50%左右,并调节了与癌症相关的关键途径.
- 该纳米颗粒配方表现出稳定性,抗瘤功效和安全性,并确定了IC50值.
结论:
- Cu2O@G-Rh2纳米粒子为甲状腺癌治疗提供了一个有前途的治疗策略.
- 这种方法显示出抑制瘤复发和转移的潜力,并具有良好的安全性.
- 该研究为THCA治疗提供了新的视角和潜在的临床应用.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K

